

**PARTICIPATION AT THE MIDCAP EVENT IN PARIS
ON 29 AND 30 SEPTEMBER 2008**

Nantes (France) – September 10, 2008

VIVALIS (Euronext Paris: VLS), a biopharmaceutical company which provides to the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases, will be participating in the Midcap Event on 29 and 30 September this year. This forum will take place at Palais Brongniart, 19 rue Notre-Dame des Victoires, 75002 Paris.

VIVALIS has recorded solid marketing development since the beginning of the year, with the signing of 4 licences. The company is set to reach, or even to exceed, its objective of 7 to 9 licences before the end of the financial year. The latest results, which are extremely conclusive and promising, plus the filing of the BMF with the FDA, allow VIVALIS to envisage an imminent acceleration in initial and milestone payments. Finally, the €6m grant from Oséo will enable VIVALIS to master and offer its clients complete processes for the production of vaccines and proteins, in order to increase still further the value creation of this platform.

The participation of VIVALIS in this forum is a way of strengthening its relations with investors and increasing its visibility in the financial community. The Midcap Event will also be an opportunity for fund managers to meet Franck Grimaud, Chief Executive Officer of VIVALIS, in order to discuss the first half-year of 2008 and to examine perspectives for the coming months.

Next official statement:

November 13, after Euronext market closing: 3rd quarter sales

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides to the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins, and develops drugs to prevent and treat viral diseases. VIVALIS' knowhow and proprietary technologies are commercially exploited in three main areas:

1. Vaccine development and manufacturing. VIVALIS grants research and commercial licences to its proprietary EBx[®] embryonic stem cell lines to pharmaceutical and biotechnology companies and to the pharmaceutical industry for the production of viral vaccines.
2. Recombinant therapeutic protein and monoclonal antibody production systems development. VIVALIS licenses to pharmaceutical and biotechnology companies its EBx[®] embryonic stem cell lines to manufacture recombinant therapeutic proteins.
3. The build-up of a proprietary portfolio of vaccines and anti-viral molecules (Hepatitis C).

Based in Nantes (France), VIVALIS was created in 1999 by Group Grimaud (1,450 employees), the n^o2 group worldwide in animal genetic breeding. VIVALIS has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial, SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

Euronext Paris Compartment C - FR0004056851
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investor relations:

VIVALIS

Franck Grimaud, C.E.O.
Email: investors@vivalis.com

NewCap

Financial communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr